Share on:
02/12/2026 09:28
New Antibody Offers Potential Breakthrough in HIV Vaccine and Therapy Development
An international research team has identified a novel antibody that targets HIV in a unique way, overcoming limitations of previously known antibodies. The study, led by Professor Dr. Florian Klein, offers new avenues for the development of both HIV-1 vaccines and therapeutic treatments, and was published in the journal “Nature Immunology.”
HIV-1 can be neutralized by antibodies that bind to vulnerable structures on the virus’s surface. One such weak point is the V3 glycan site of the virus’s surface protein. This target structure plays a key role in the virus’s entry into human cells and has long been a focus for developing new immunotherapeutic and preventative approaches. However, most antibodies identified to date have only been effective at recognizing a subset of the HIV-1 variants circulating globally.
The newly described antibody, designated 007, attacks the V3 glycan site in a different manner than previously known antibodies. Unlike classical V3 antibodies, its binding isn’t dependent on a specific sugar structure that HIV-1 frequently alters to evade the immune response. In laboratory tests, 007 remains effective against virus variants that are resistant to classical V3 antibodies. In a mouse model with human immune cells, 007 also effectively improved existing V3 antibody therapy, requiring the virus to develop multiple changes simultaneously to escape the antibody treatment. A key finding of the study is that 007 fills gaps in the activity of classical V3 antibodies, supporting antibody therapy combinations that can more effectively disable the virus overall.
“The V3 glycan site has long been considered a vulnerability of HIV-1, but has so far only been incompletely utilized therapeutically and for vaccine development,” explained Dr. Lutz Gieselmann, the study’s first author. Dr. Malena Rohde, also an author of the operate, added: “The identification of antibody 007 demonstrates that this vulnerability is much more versatile than previously thought, and also opens up new perspectives for vaccine development.”
These research findings are significant for the development of both new combination therapies, and vaccines. For use in HIV immunotherapy, 007 has already been exclusively licensed to the company Vir, in collaboration with the Gates Foundation to support their charitable purposes, and is undergoing preclinical development with support from the Cologne-based start-up Togontech.
This study was supported by the Gates Foundation, the German Research Foundation (DFG), the German Center for Infection Research (DZIF), and the European Research Council (ERC).
Presse and Kommunikation:
Jan Voelkel
+49 221 470 2356
j.voelkel@verw.uni-koeln.de
Verantwortlich: Dr. Elisabeth Hoffmann – e.hoffmann@verw.uni-koeln.de
Original publication:
Zur Publikation:
https://www.nature.com/articles/s41590-025-02385-3
Images
Criteria of this press release:
Journalists
Biology, Medicine, Nutrition / healthcare / nursing
transregional, national
Research results
German
